作者
R Berecz, P Dorado, ADL Rubia, MC Caceres, I Degrell, A LLerena
发表日期
2004/8/1
来源
Current drug targets
卷号
5
期号
6
页码范围
573-579
出版商
Bentham Science Publishers
简介
In the recent years it has been increasingly recognized that pharmacogenetical factors play an important role in the drug treatment. These factors may influence the appearance of side-effects and drug interactions due to interindividual differences in the activity of metabolizing enzymes. Risperidone in humans is mainly metabolized to 9-hydroxyrisperidone by the polymorphic cytochrome enzyme P450 2D6 (CYP2D6). Plasma concentrations of risperidone and 9-hydroxyrisperidone show large interindividual variability, which may be partly related to the activity of the CYP2D6 enzyme. Around seven percent of Caucasians have a genetically inherited impaired activity of the CYP2D6 enzyme. Debrisoquine metabolic ratio (a marker of CYP2D6 activity) and the number of CYP2D6 active genes have been related to risperidone plasma concentrations among patients during steadystate conditions. A large number drugs …
引用总数
2005200620072008200920102011201220132014201520162017201820192020202120222023202423953423785325223315
学术搜索中的文章